Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Halozyme Therapeutics reported strong second quarter 2026 financial and operating results, driven by significant growth in royalty revenues from its ENHANZE technology platform.</li><li>Total revenues rose 48% year-over-year to $481 million, while royalty revenues increased 50% to $308 million.</li><li>Results exceeded company expectations, supported by six ENHANZE-enabled products.</li></ul>

Halozyme Therapeutics reported strong second quarter 2026 financial and operating results, driven by significant growth in royalty revenues from its ENHANZE technology platform.Total revenues rose 48% year-over-year to $481 million, while royalty revenues increased 50% to $308 million.Results exceeded company expectations, supported by six ENHANZE-enabled products.

Halozyme Therapeutics’ 50% Royalty Surge — Is ENHANZE Still Just Getting Started?

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Halozyme's core value proposition is its proprietary ENHANZE® drug delivery technology, which enables the conversion of intravenous therapies to simpler subcutaneous injections, driving a high-margin royalty revenue stream through partnerships with major pharmaceutical companies.</li>
  <li>The company has demonstrated a strong growth trajectory, with significant year-over-year increases in revenue and profitability, and has a stated goal of surpassing $1 billion in annual royalty revenues.</li>
  <li>Strategic acquisitions of new drug delivery technologies (Hypercon and Surf Bio) aim to extend the company's intellectual property runway and revenue durability beyond the patent expirations of the core ENHANZE platform, mitigating a key long-term risk.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Halozyme's core value proposition is its proprietary ENHANZE® drug delivery technology, which enables the conversion of intravenous therapies to simpler subcutaneous injections, driving a high-margin royalty revenue stream through partnerships with major pharmaceutical companies.
  The company has demonstrated a strong growth trajectory, with significant year-over-year increases in revenue and profitability, and has a stated goal of surpassing $1 billion in annual royalty revenues.
  Strategic acquisitions of new drug delivery technologies (Hypercon and Surf Bio) aim to extend the company's intellectual property runway and revenue durability beyond the patent expirations of the core ENHANZE platform, mitigating a key long-term risk.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Halozyme Therapeutics (HALO US) - Aug 2026

<ul><li>Halozyme Therapeutics reported a strong start to 2026, driven by the increasing adoption of its ENHANZE technology enabling subcutaneous drug delivery.</li><li>The company’s first-quarter revenue grew 42% year-over-year to $377 million, primarily fueled by a 43% rise in royalty revenues to $241 million.</li><li>These royalties stem from a portfolio of 10 approved ENHANZE-enabled products, including DARZALEX subcutaneous, VYVGART Hytrulo, and PHESGO, which collectively continue to demonstrate robust growth.</li></ul>

Halozyme Therapeutics reported a strong start to 2026, driven by the increasing adoption of its ENHANZE technology enabling subcutaneous drug delivery.The company’s first-quarter revenue grew 42% year-over-year to $377 million, primarily fueled by a 43% rise in royalty revenues to $241 million.These royalties stem from a portfolio of 10 approved ENHANZE-enabled products, including DARZALEX subcutaneous, VYVGART Hytrulo, and PHESGO, which collectively continue to demonstrate robust growth.

Halozyme Therapeutics’ $1 Billion Royalty Milestone — Is The Market Missing ENHANZE?

<ul><li>Halozyme Therapeutics delivered a significant year of growth in 2025, highlighted by expanding its drug delivery portfolio and achieving remarkable financial performance.</li><li>The company achieved a 38% increase in total revenue, reaching a record $1.4 billion, mainly driven by a substantial 52% growth in royalty revenue, totaling $868 million.</li><li>This robust performance was fueled by the continued adoption of ENHANZE-enabled products, such as DARZALEX SC, PHESGO, and VYVGART Hytrulo.</li></ul>

Halozyme Therapeutics delivered a significant year of growth in 2025, highlighted by expanding its drug delivery portfolio and achieving remarkable financial performance.The company achieved a 38% increase in total revenue, reaching a record $1.4 billion, mainly driven by a substantial 52% growth in royalty revenue, totaling $868 million.This robust performance was fueled by the continued adoption of ENHANZE-enabled products, such as DARZALEX SC, PHESGO, and VYVGART Hytrulo.

Halozyme Therapeutics: ENHANZE, Hypercon, and the Blueprint for Durable Biotech Cash Flows!

<ul><li>Halozyme Therapeutics' third quarter 2025 results show a strong financial performance driven by its ENHANZE drug delivery technology and significant growth in royalty revenue.</li><li>The company reported an impressive 52% increase year-over-year in royalty revenue, reaching $236 million.</li><li>This growth, along with total revenue of $354 million, reflects a 22% increase year-over-year.</li></ul>

Halozyme Therapeutics' third quarter 2025 results show a strong financial performance driven by its ENHANZE drug delivery technology and significant growth in royalty revenue.The company reported an impressive 52% increase year-over-year in royalty revenue, reaching $236 million.This growth, along with total revenue of $354 million, reflects a 22% increase year-over-year.

Halozyme’s Breakthrough Moment: Could Its Game-Changing Subcutaneous Tech Disrupt Cancer Care Forever?

United States

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Halozyme Therapeutics (HALO US)

Halozyme Therapeutics’ 50% Royalty Surge — Is ENHANZE Still Just Getting Started?

Halozyme Therapeutics reported strong second quarter 2026 financial and operating results, driven by significant growth in royalty revenues from...

Baptista Research

Primer: Halozyme Therapeutics (HALO US) - Aug 2026

Halozyme's core value proposition is its proprietary ENHANZE® drug delivery technology, which enables the conversion of intravenous therapies to...

αSK Primers

Halozyme Therapeutics’ $1 Billion Royalty Milestone — Is The Market Missing ENHANZE?

Halozyme Therapeutics reported a strong start to 2026, driven by the increasing adoption of its ENHANZE technology enabling subcutaneous drug...

Baptista Research

Halozyme Therapeutics: ENHANZE, Hypercon, and the Blueprint for Durable Biotech Cash Flows!

Halozyme Therapeutics delivered a significant year of growth in 2025, highlighted by expanding its drug delivery portfolio and achieving...

Baptista Research

Halozyme’s Breakthrough Moment: Could Its Game-Changing Subcutaneous Tech Disrupt Cancer Care Forever?

Halozyme Therapeutics' third quarter 2025 results show a strong financial performance driven by its ENHANZE drug delivery technology and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)